Centers for Medicare & Medicaid Services Administrator Seema Verma today discussed a number of efforts underway at the agency, including many to reduce regulatory burdens on providers. 
 
鈥淲e recognize that some regulations are necessary to ensure patient safety, quality and program integrity, but many are redundant, ineffective and have a negative effect on patient care by taking providers away from their primary mission 鈥 improving their patients鈥 health outcomes,鈥 Verma said. 
 
She discussed the agency鈥檚 proposal to implement the Meaningful Measures initiative, which would remove 18 measures from the inpatient quality reporting program and 鈥渄e-duplicate鈥 21 measures, meaning that they would be used in only one program rather than multiple programs. 
 
Verma also said the agency is considering actions to provide relief from the Stark Law. 

鈥淲e intend to leave in place the law鈥檚 important protections for our beneficiaries and for the [Medicare] Trust Fund, while not penalizing providers who are taking brave steps away from fee-for-service,鈥 she said. 
 
Last year, AHA released a report that found non-clinical regulatory requirements cost providers nearly $39 billion a year and divert clinicians from patient care. 
 
Meanwhile, Verma said the agency is continuing to 鈥渕ove away from a fee-for-service approach to a system that is value-based and that rewards value over volume.鈥 

[For additional highlights from the AHA Annual Membership meeting, click here.] 

She discussed a number of key initiatives the agency will unveil this year, including developing new payment models through the Center for Medicare and Medicaid Innovation. Those models will focus on, among other areas, innovative ways to pay for drugs, primary care and conditions with serious medical conditions, and promoting competition in Medicare Advantage, Verma said. 
 
In addition, Verma spoke about the need to address the rising cost of prescription drugs, which she said is important to President Trump. He is expected to make a major speech soon on the issue. 
 
鈥淲hen patients cannot afford their medication, adherence goes down and patients get sicker,鈥 Verma said. 鈥淟ife-saving treatments don鈥檛 mean anything if a patient can鈥檛 afford them.鈥 

Related News Articles

Headline
AHA May 23 submitted recommendations to the Department of Justice and Federal Trade Commission in response to the agencies鈥 requests for information on鈥
Headline
The Department of Health and Human Services May 20 announced it has identified specific pricing targets for pharmaceutical manufacturers to meet to satisfy鈥
Headline
The Centers for Medicare & Medicaid Services May 12 released draft guidance for the third round of negotiations for the Medicare Drug Price Negotiation鈥
Headline
The White House May 12 released an executive order to reduce prescription drug costs by allowing consumers to make direct purchases from drug manufacturers at鈥
Headline
The AHA May 12 responded to the Office of Management and Budget's April 11 request for information on regulatory relief, making 100 suggestions to the Trump鈥
Headline
The Trump administration May 5 issued two executive orders on pharmaceutical manufacturing and life-sciences research. The first executive order, "鈥